From Early Stage to Resistance: ALINA Study Insights and ALK Inhibitor Sequencing Strategies

, , ,

Peer Exchange | <b>Latest Advances in ALK-Positive and BRAF-Positive V600E NSCLC: Efficacy Updates, Brain Metastases Management, and Optimal Treatment Sequencing </b>

Panelists discuss the findings from the ALINA study on adjuvant alectinib vs chemotherapy in resected ALK-positive NSCLC, considering how these results may influence early-stage management, sequencing strategies for ALK inhibitors, and the role of resistance mechanisms in treatment decisions.

  1. Dr Rotow: The ALINA study included exploratory biomarker analyses in patients with resected ALK-positive NSCLC treated with adjuvant alectinib vs chemotherapy. (Solomon BJ, et al. 2024. ESMO. 1206MO)
  2. What are your thoughts on these findings, and how might they impact your approach to early-stage ALK-positive NSCLC management?
  3. What strategies are you currently using for sequencing ALK inhibitors?
  4. How do resistance mechanisms influence your sequence decisions?
  5. What data support using lorlatinib in the first-line setting vs reserving it for later lines?

Related Content:

Future Directions in ALK-Positive and BRAF-Positive NSCLC Management
Precision BRAF Therapy: Optimizing Dosing, Sequencing, and Toxicity Management in NSCLC
Long-Term Outcomes of BRAF-MEK Inhibitor Combinations